GSEP
PPH icon

Golden State Equity Partners’s VanEck Pharmaceutical ETF PPH Stock Holding History

Golden State Equity Partners’s Portfolio PPH Stock Details PPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-200
Closed -$20.8K – 1366
2026
Q1 		$20.8K Buy
+200
New +$21.3K ﹤0.01% 1086

Other funds holding PPH

Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
JSAM
J. Safra Asset Management New York $2.17B AUM 29.66% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
AT
Avalon Trust Santa Fe, New Mexico $1.63B AUM 42.75% 1-Year Est. Return
AWC
Adamsbrown Wealth Consultants Wichita, Kansas $530M AUM 23.21% 1-Year Est. Return

Golden State Equity Partners's PPH Position: Q2 2026 in Review

Golden State Equity Partners sold out of VanEck Pharmaceutical ETF (PPH) in Q2 2026, closing a stake of 200 shares — an estimated $20.8K sold.

Golden State Equity Partners first reported a position in PPH in Q1 2026 and held it in 1 quarter. The position peaked at $20.8K in Q1 2026. 148 funds tracked by Wall St. Rank hold PPH as of Q2 2026.

  • Golden State Equity Partners reported no remaining VanEck Pharmaceutical ETF position as of Q2 2026 after selling out during the quarter.
  • Golden State Equity Partners sold 200 VanEck Pharmaceutical ETF shares in Q2 2026, an estimated $20.8K.
  • Golden State Equity Partners first reported a position in VanEck Pharmaceutical ETF in Q1 2026 and held it in 1 quarter.
  • Golden State Equity Partners's VanEck Pharmaceutical ETF position peaked at $20.8K in Q1 2026.
  • 148 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q2 2026.

Based on Golden State Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.